Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support

被引：8
作者：
Clemons, M [1 ]
机构：
[1] Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada
来源：
CLINICAL ONCOLOGY | 2004年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.clon.2004.01.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In summary, the use of bisphosphonates for bone metastases has led to a major improvement in the management of women with metastatic breast cancer. However, the magnitude of benefit, who to treat, when to treat, and for how long remains unclear. A real need exists for randomised trials on the continued use of bisphosphonates after skeletal events while on a bisphosphonate, and also their role in the management of patients with poor prognosis disease. © 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：108 / 111
页数：4
相关论文
共 32 条
  • [1] BLOOMFIELD D, 1999, CURR ONCOL, V6, P144
  • [2] Bisphosphonates for cancer patients: why, how, and when?
    Body, JJ
    Mancini, I
    [J]. SUPPORTIVE CARE IN CANCER, 2002, 10 (05) : 399 - 407
  • [3] Dosing regimens and main adverse events of bisphosphonates
    Body, JJ
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 49 - 53
  • [4] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    Body, JJ
    Diel, IJ
    Lichinitser, MR
    Kreuser, ED
    Dornoff, W
    Gorbunova, VA
    Budde, M
    Bergström, B
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (09) : 1399 - 1405
  • [5] *BREAST CANC DIS S, 2002, US BISPH PAT BON MET
  • [6] CLEMONS M, IN PRESS CAN J CLIN
  • [7] Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (03) : 165 - 176
  • [8] Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO
  • [9] 2-Z
  • [10] Dranitsaris G., 2001, J ONCOL PHARM PRACT, V7, P27, DOI [10.1191/1078155201jp077oa, DOI 10.1191/1078155201JP077OA]
1234